New immune cells combined with drugs for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new immune cell therapy (gamma-delta T cells) combined with other drugs for people with liver cancer who have not had treatment before. It may help shrink the tumor or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with hepatocellular carcinoma (a type of liver cancer) at a stage B or C.
- You have not received any previous cancer treatment.
- Your liver function is good enough (Child-Pugh class A or B, score 5-9).
- You are willing to use birth control during the study and for 30 days after.
- You can attend all study visits and follow the protocol.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination therapy using special immune cells (gamma-delta T cells) along with targeted drugs and immunotherapy for people with advanced liver cancer that is no longer responding to standard treatment. The goal is to see if this approach can help shrink tumors or slow their growth.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests using your own immune cells (tumor-infiltrating lymphocytes) to fight advanced liver cancer. It may help if you have Barcelona Clinic Liver Cancer (BCLC) stage B or C and your liver function is still fairly good.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial is testing a new combination: a virus injected directly into the tumor, plus two drugs (tislelizumab and lenvatinib) that boost the immune system and block tumor blood supply. It is for people with advanced liver cancer who have not had similar treatments before.
This trial is for people with advanced liver cancer (HCC) that has spread outside the liver or into major blood vessels. It tests combining a procedure called TACE with immunotherapy (PD-1/PD-L1 inhibitors) and targeted drugs to see how well they work together.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.